New Rituximab Formulation Approved for Some Lymphomas, Leukemia

The FDA has approved a new formulation of rituximab, Rituxan Hycela, that reduces treatment administration time for patients with several types of blood cancer.

Cancer Currents: An NCI Cancer Research Blog